Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Anticancer Res. 2013 Jun;33(6):2473-80.
Multifunctional Y-box Binding Protein-1 (YB1) is correlated with a poor outcome in breast cancer. We found YB1 expression to be regulated by antiestrogens commonly used in the hormonal therapy of breast cancer and known as activators of Transforming Growth Factor-β (TGFβ). Thus, a putative influence of YB1 on TGFβ signaling should be investigated.
The effect of YB1 on TGFβ signaling was monitored by expression analysis and reporter gene assays in breast cancer cells overexpressing YB1 and treated with antiestrogens.
Antiestrogen-mediated inhibition of estrogen receptor-α led to a suppression of YB1 protein synthesis. On the other hand, YB1 was found to be an enhancer of TGFβ signaling.
High levels of YB1 expression lead to a stimulation of TGFβ pathways, thereby counteracting antihormonal breast cancer therapy and representing a putative resistance mechanism.
多功能 Y 盒结合蛋白-1(YB1)与乳腺癌的不良预后相关。我们发现 YB1 的表达受到常用于乳腺癌激素治疗的抗雌激素的调节,这些抗雌激素被称为转化生长因子-β(TGFβ)的激活剂。因此,应该研究 YB1 对 TGFβ 信号传导的潜在影响。
通过在过表达 YB1 的乳腺癌细胞中进行表达分析和报告基因检测,监测 YB1 对 TGFβ 信号传导的影响,并使用抗雌激素进行处理。
抗雌激素介导的雌激素受体-α抑制导致 YB1 蛋白合成的抑制。另一方面,发现 YB1 是 TGFβ 信号传导的增强子。
高水平的 YB1 表达导致 TGFβ 途径的刺激,从而抵消了抗激素乳腺癌治疗,并代表了一种潜在的耐药机制。